LYONS GARY A 4

What Happened

• Gary A. Lyons, a director of Travere Therapeutics (TVTX), was granted a total of 16,000 shares on 2026-05-19 as part of the company's director compensation program. The filing shows a 4,000-share award and a 12,000-share derivative award, each with an acquisition price of $0.00 (transaction code A). Footnotes state these are automatic equity grants under the Issuer’s 2018 Equity Incentive Plan and that the award vests over one year.
• This was a grant/award (not a purchase or sale) and therefore reflects routine compensation rather than an open‑market investment.

Key Details

• Transaction date: 2026-05-19; Filing date: 2026-05-21 (filed within the typical 2‑business‑day Form 4 window).
• Securities: 4,000 shares acquired (A) at $0.00; 12,000 derivative shares awarded (A) at $0.00.
• Shares owned after transaction: not specified in the information provided in this summary.
• Footnotes: F1—Automatic equity grant under the 2018 Equity Incentive Plan for non‑employee directors; F2—award vests over a one‑year period.
• Transaction type code: A = Award/Grant.

Context

• Director equity grants are common as part of non‑employee director compensation and are typically designed to align interests with shareholders. Because these are awards (not purchases), they should not be read as a direct personal investment signal.
• The 12,000 "derivative" shares refer to an equity award that will typically convert into common shares as it vests; consult the full Form 4 for precise terms if you need more detail.